Background

eMed, Senior M&A Analyst Miami, FL · January 2026 – present

• Direct eMed’s buy-side function from origination through close.
• Advanced 5 of 27 targets screened in 1H26; originated 3 directly.
• Negotiate purchase agreements and deal structures directly with founders and their counsel.
• Maintain eMed’s consolidated three-statement forecast model, and build forward cases for M&A targets, direct early-stage investments, and strategic partnerships.
• Serve as Chief of Staff to the Executive Chairman, directing family office diligence across portfolio companies, direct investments, and public markets.

eMed, M&A Analyst September 2022 – January 2026

• Executed buy-side, tender offer, and capital-raise mandates across healthcare technology.
• Owned consolidated FP&A across operating plans, forecasts, and CEO budget reviews.

Zurn Elkay Water Solutions, M&A Analyst, Corporate Development NYSE: ZWS · Milwaukee, WI · December 2021 – August 2022

• Led NDA negotiations and drafted LOIs from outreach through term-sheet stage.
• Built the quarterly M&A update presented to the Board of Directors.

Marquette University, B.S., Business Economics & Finance Milwaukee, WI · May 2021

• Investment Analysis concentration.
• Applied Investment Management Program, managing equity research for a $3M endowment.

Published equity research: EnerSys (NYSE: ENS), “Recharging Upside,” AIM Equity Fund, April 2020